The presence of heterogeneous vancomycin-intermediate Staphylococcus aureus (heteroVISA) in a major Malaysian hospital

Medical Journal of Malaysia

Volumn 67, Issue 3, 2012, Pages 269-273

  Ahmad, Norazah ^a   Ling, Law Ngiik ^b   Ghani, Mohamed Kamel Abd ^b   Nawi, Salbiah ^c  

^a INSTITUTE FOR MEDICAL RESEARCH   (Malaysia)

^b UNIVERSITI KEBANGSAAN MALAYSIA   (Malaysia)

^c Selayang Hospital   (Malaysia)

Author keywords

Etest GRD; Heterovisa; MRSA; Population analysis; Pulsed field gel electrophoresis

Indexed keywords

VANCOMYCIN;

ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM DETECTION; BACTERIUM IDENTIFICATION; BACTERIUM ISOLATE; DRUG EFFICACY; ETEST GLYCOPEPTIDE RESISTANCE DETECTION; HETEROGENOUS VANCOMYCIN INTERMEDIATE STAPHYLOCOCCUS AUREUS; HOSPITAL; MALAYSIA; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; MOLECULAR PHYLOGENY; NONHUMAN; PULSED FIELD GEL ELECTROPHORESIS; STAPHYLOCOCCUS AUREUS;

ANTI-BACTERIAL AGENTS; DNA, BACTERIAL; GENOTYPE; HOSPITALS; HUMANS; MALAYSIA; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCAL INFECTIONS; VANCOMYCIN RESISTANCE;

EID: 84864489980     PISSN: 03005283     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Ministry of Health, Malaysia. National Surveillance of Antibiotic Resistance Report 2009. Available at: www.imr.gov.my/report/nsar2009.htm.
2. Hiramatsu K, Aritaka N, Hanaki H et al. Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin. Lancet 1997; 350: 1670-1673.
3. Ariza J, Pujol M, Cabo J et al. Vancomycin in surgical infections due to methicillin-resistant Staphylococcus aureus with heterogeneous resistance to vancomycin. Lancet; 1999: 353: 1587-1588.
4. Kim MN, Pai CH, Woo JH, Ryu JS, Hiramatsu K. Vancomycin-intermediate Staphylococcus aureus in Korea. J Clin Microbiol 2000; 38: 3879-3881.
5. Marchese A, Balistreri G, Tonoli E, Bebbia EA, Schito GC. Heterogenous vancomycin-resistance in methicillin-resistant Staphylococus aureus strains in a large Italian hospital. J Clin Microbiol 2000; 38: 866-869.
6. Sng LH, Koh TH, Wang GC, Hsu LY, Kapi M, Hiramatsu K. Heterogeneous vancomycin-resistant Staphylococcus aureus (hetero-VISA) in Singapore. Int J Antimicrob Agents 2005; 25: 177-179.
7. Trakulsomboon S, Danchaivijitr S, Rongrungruang Y et al. First report of methicillin-resistant Staphylococcus aureus with reduced susceptibility to vancomycin in Thailand. J Clin Microbiol 2001; 39: 591-595.
8. Wong SS, Ng TK, Yam WC. Bacteremia due to Staphylococcus aureus with reduced susceptibility to vancomycin. Diagn Microbiol Infect Dis 2000; 36: 261-268.
9. Sakoulas G, Moise-Broder PA, Schentag J, Forrest A, Moellering RC Jr, Eliopoulos GM. Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia. J Clinical Microbiol 2004; 42: 2398-2402.
10. Sader HS, Becke, HK, Moe GJ, Jones RN. Antimicrobial activity of daptomycin tested against Staphylococcus aureus with vancomycin MIC of 2 microg/mL isolated in the United States and European hospitals (2006-2008). Diagn Microbiol and Infect Dis 2010; 66: 329-331.
11. Wong SS, Ho PL, Woo PC, Yuen KY. Bacteremia caused by staphylococci with inducible vancomycin heteroresistance. Clin Infect Dis 1999; 29: 760-7.
12. Norazah A, Lim VK, Rohani MY, Alfizah H, Koh YT, Kamel AG. A major methicillin-resistant Staphylococcus aureus clone predominates in Malaysian hospitals. Epidemiol Infect 2003; 130: 407-411.
13. Tenover FC, Sinner SW, Segal RE et al. Characterisation of a Staphylococcus aureus strain with progressive loss of susceptibility to vancomycin and daptomycin during therapy. Int J Antimicrob Agents 2009; 33: 564-568.
14. Wootton M, Howe RA, Hillman R, Walsh TR, Bennett PM, MacGowan AP. A modified population analysis profile (PAP) method to detect hetero-resistance to vancomycin in Staphylococcus aureus in a UK hospital. J Antimicrob Chemother 2001; 47: 399-403.
15. Leonard SN, Rossi KL, Newton KL, Rybak MJ. Evaluation of the Etest GRD for the detection of Staphylococcus aureus with reduced susceptibility to glycopeptides. J Antimicrobial Chemother 2009; 63: 489-492.
16. McDougal LK, Steward CD, Killgore GE, Chaitram JM, McAllister SK, Tenover FC. Pulsed-field gel electrophoresis typing of oxacillin-resistant Staphylococcus aureus isolates from the United States: establishing a national database. J Clin Microbiol 2003; 41: 5113-5120.
17. Liu C, Chambers HF. Staphylococcus aureus with heterogeneous resistance to vancomycin: epidemiology, clinical significance, and critical assessment of diagnostic methods. Antimicrob Agents Chemother 2003; 47: 3040-3045.
18. Maor Y, Hagin M, Belausov N, Keller N, Ben-David D, Rahav G. Clinical features of heteroresistant vancomycin-intermediate Staphylococcus aureus bacteremia versus those of methicillin-resistant S. aureus bacteremia. J Infect Dis 2009; 199: 619-624.
19. Howden BP, Johnson PD, Ward PB, Stinear TP, Davies JK. Isolates with low-level vancomycin resistance associated with persistent methicillin-resistant Staphylococcus aureus bacteremia. Antimicrob Agents Chemother 2006; 50: 3039-3047.
20. Rong SL, Leonard SN. Heterogeneous vancomycin resistance in Staphylococcus aureus: a review of epidemiology, diagnosis, and clinical significance. Ann Pharmacother 2010; 44: 844-850.
21. Charles PG, Ward PB, Johnson PD, Howden BP, Grayson ML. Clinical features associated with bacteraemia due to heterogenous vancomycin-intermediate Staphylococcus aureus Clin Infect Dis 2004; 38:448-451.
22. Neoh HM, Hori S, Komatsu M et al. Impact of reduced vancomycin susceptibility on the therapeutic outcome of MRSA bloodstream infections. Annals of Clinical Microbiology and Antimicrobials 2007; 6:13. Available at: www.ann-clinmicrob.com/content/6/1/13.
23. Moise PA, Schentag JJ. Vancomycin treatment failures in Staphylococcus aureus lower respiratory tract infections. Int J of Antimicrob Agents 2000; 16 (Suppl 1): S31-S34.
24. Hiramatsu K. Vancomycin resistance in staphylococci. Drug Resist Updates 1998; 1: 135-150.
25. Hidayat LK, Hsu DI, Quist R, Shriner KA, Wong-Beringer A. High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity. Arch Int Med 2006; 166: 2138-2144.
26. Mohr JF, Murray BE. Point: Vancomycin is not obsolete for the treatment of infection caused by methicillin-resistant Staphylococcus aureus. Clin Infect Dis 2007; 44: 1536-1542.
27. Ahmad N, Nawi S, Rajasekaran G et al. Increased vancomycin minimum inhibitory concentration among Staphylococcus aureus isolates in Malaysia. J Med Microbiol 2010; 59: 1530-1532.
28. Brunet, F., Vedel, G., Dreyfus F et al. Failure of teicoplanin therapy in two neutropenic patients with staphylococcal septicemia who recovered after administration of vancomycin. Eur J of Clin Microbiol Infect Dis 1990; 9: 145-147.
29. Kaatz, GW, Seo SM, Dorman NJ, Lerner SA. Emergence of teicoplanin resistance during therapy of Staphylococcus aureus endocarditis. Journal of Infectious Diseases 1990; 162: 103-108.
30. Hanaki H, Kuwahara-Arai K, Boyle-Vavra S, Daum RS, Labischinski H, Hiramatsu K. Activated cell-wall synthesis is associated with vancomycin resistance in methicillin-resistant Staphylococcus aureus clinical strains Mu3 and Mu50. J Antimicrob Chemother 1998; 42: 199-209.
31. Norazah A, Salbiah N, Nurizzat M, Santhana, R. Vancomycin treatment failure in a vancomycin susceptible methicillin-resistant Staphylococcus aureus (MRSA) infected patient. Med J Mal 2009; 64: 166-167.
32. Horne KC, Howden BP, Grabsch EA et al. Prospective comparison of the clinical impacts of heterogeneous vancomycin-intermediate methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-susceptible MRSA. Antimicrob Agents Chemother 2009; 53: 3447-3452.
33. Pina P, Marliere C, Vandenesch F, Bedos JP, Etienne J, Allouch PY. An outbreak of Staphylococcus aureus strains with reduced susceptibility to glycopeptides in a French general hospital. Clin Infect Dis 2000; 31: 1306-1308.
34. Howden BP, Ward PB, Charles PG et al. Treatment outcomes for serious infections caused by methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility. Clin Infect Dis 2004; 38: 521-528.
35. Tenover FC, Arbeit RD, Goering RV x0 Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typing. J Clin Microbiol 1995; 33: 2233-2239.